Anavex Life Sciences Corp (AVXL)

[TrueTrades]

§ Great post!

The company chose to approach the study in a manner which has been suggested by the powers that be. The intent is to power an efficient 100 - 300 cohort P3 which will, indisputably, demonstrate the effectiveness of the treatment as real-world results are expressed in the patients and through SOA bio-markers. The clinical results of enrolles who have been treated for two years into a 8-12 year progressive disease will solidify any preclinical findings.

The implications of our sigma-1 + muscarinic activator approach are genuinely significant...make no mistake.

And 3-71 is far-more potent...as an aside...and LSB'd!
§AVXL